“At Ranok, we are dedicated to creating the next generation of much safer and more efficacious cancer therapies. Our vision is nothing less than to profoundly transform the lives of patients and their families.”
Weiwen Ying, Ph.D. – Founder & CEO
Ranok is a privately held, pre-clinical stage biopharmaceutical company that is pioneering an innovative targeted protein degradation technology for the discovery and development of novel therapeutics. Ranok was founded by a leadership team composed of industry veterans from both Chinese and American biotech and pharmaceutical companies and is based in two of the world’s leading centers of innovation and medical research: Hangzhou, China and Boston, Massachusetts USA.
Chemically induced, targeted protein degradation (TPD) has recently emerged as an exciting new modality for small molecule drug development. Ranok has developed an innovative, next-generation TPD technology that engages different underlying biological processes and has unique advantages over competing TPD approaches. Ranok’s pipeline includes both well-validated and novel drug targets that are implicated in cancer and other diseases with significant unmet medical needs.
Ranok Therapeutics was founded by industry veterans from both Chinese and American biotech and pharmaceutical companies. By bringing together perspectives and expertise that span the Pacific, our goal is to change the limits of what is possible and create the biopharmaceutical company of tomorrow.
We are looking for team members with the passion, discipline and scientific excellence to help us discover a better tomorrow for cancer patients and their families. Exciting job opportunities are available in both China and the United States.